The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study
Liraglutide was associated with the highest risk of clinically relevant cholelithiasis than semaglutide, and dulaglutide in patients with T2D.
Authors
- Rasha Ibrahim Salama (ORCID: https://orcid.org/0000-0001-6285-8465)
- Mohamed Emara (ORCID: https://orcid.org/0000-0002-1504-7851)
- Rehab Elsayed Marzouk (ORCID: https://orcid.org/0000-0002-5551-1540)
- Mohammed Ali Gameil (ORCID: https://orcid.org/0000-0002-9342-6451)
- Abeer Abdelkader (ORCID: https://orcid.org/0009-0008-2924-3571)
- Elshahat A. Yousef
Institutions
- Kafrelsheikh University (EG)
- Mansoura University (EG)
- Zagazig University (EG)
- Saad Specialist Hospital (SA)
- Helwan University (EG)
Publication Details
- Journal
- Diabetology & Metabolic Syndrome
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1186/s13098-024-01526-2
- Citations
- 9
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.22
Funders
- Mansoura University